Your activity: 58 p.v.
< Back
your limit has been reached. plz Donate us to allow your ip full access, Email: sshnevis@outlook.com

Schedule for vaccination using 23-valent polysaccharide vaccine (PPSV23) after 13-valent pneumococcal conjugate vaccine (PCV13) for children aged ≥2 years with underlying medical conditions

Schedule for vaccination using 23-valent polysaccharide vaccine (PPSV23) after 13-valent pneumococcal conjugate vaccine (PCV13) for children aged ≥2 years with underlying medical conditions
Group Schedule for PPSV23 Revaccination with PPSV23
Children who have sickle cell disease 1 dose of PPSV23 administered at age ≥2 years and ≥8 weeks after last indicated dose of PCV13 1 dose 3 or 5 years after the first dose of PPSV23*
Children who have other types of functional or anatomic asplenia or are immunocompromised 1 dose of PPSV23 administered at age ≥2 years and ≥8 weeks after last indicated dose of PCV13 1 dose 5 years after the first dose of PPSV23
Immunocompetent children with chronic illness 1 dose of PPSV23 administered at age ≥2 years and ≥8 weeks after last indicated dose of PCV13 Not recommended
* For patients with sickle cell disease, some experts recommend an interval of three years between the first and second dose of PPSV23[1], whereas others recommend an interval of five years[2-5].
¶ Chronic heart disease, chronic lung disease, diabetes mellitus, cerebrospinal fluid leaks, or cochlear implant.
References:
  1. National Heart, Lung, and Blood Institute. Evidence-based management of sickle cell disease. Expert Panel Report, 2014. Available at: www.nhlbi.nih.gov/health-pro/guidelines/sickle-cell-disease-guidelines (Accessed on June 12, 2015).
  2. Pneumococcal infections. In: Red Book: 2018 Report of the Committee on Infectious Diseases, 31st ed, Kimberlin DW, Brady MT, Jackson MA, Long SS (Eds), American Academy of Pediatrics, Itasca, IL 2018. p.639.
  3. Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among children aged 6-18 years with immunocompromising conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2013; 62:521.
  4. Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 2014; 58:e44.
Graphic 79553 Version 9.0